Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 1;38(13):1890-1892.
doi: 10.1097/QAD.0000000000003984. Epub 2024 Sep 26.

CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine

Camilla Muccini  1 , Nicola Gianotti  1 , Riccardo Lolatto  1 , Silvia Nozza  1   2 , Sara Diotallevi  1 , Antonella Castagna  1   2
Affiliations

CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine

Camilla Muccini et al. AIDS. .

Abstract

Our study assessed the CD4+/CD8+ ratio in people with HIV (PWH) switching from a second-generation integrase inhibitor regimen to long-acting cabotegravir (CAB) and rilpivirine (RPV). Over one year, we observed a significant improvement in the CD4+/CD8+ ratio; In addition, our data showed that time spent in CAB+RPV was significantly associated with an increased CD4+/CD8+ ratio. These findings suggest that long-acting therapy may enhance immune recovery, also in treatment-experienced PWH.

PubMed Disclaimer

References

    1. Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, Cingolani A, et al. CD4 + /CD8 + ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study . Lancet HIV 2015; 2:e98–e106.
    1. Sigel K, Wisnivesky J, Crothers K, Brown ST, Rimland D, Rodriguez-Barradas MC, Gibert C, et al. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study . Lancet HIV 2017; 4:e67–e73.
    1. Castilho JL, Bian A, Jenkins CA, Shepherd BE, Sigel K, Gill MJ, Kitahata MM, et al. CD4 + /CD8 + ratio and cancer risk among adults with HIV . J Natl Cancer Inst 2022; 114:854–862.
    1. Muccini C, Gianotti N, Diotallevi S, Lolatto R, Spagnuolo V, Canetti D, et al. One-year of long-acting cabotegravir and rilpivirine in people with HIV and a long exposure to antiretroviral therapy: data from the SCohoLART study . Open Forum Infect Dis 2024; 11:ofae326.
    1. Herrera S, Fernandez-Felix BM, Hunt PW, Deeks SG, Sainz T, Heath SL, et al. Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort . J Antimicrob Chemother 2020; 75:1604–1610.